(Reuters) – The U.S. Food and Drug Administration declined to approve Blueprint Medicines Corp’s therapy for previously treated patients with a type of cancer that affects the stomach and small intestine, the drugmaker said on Friday.
The therapy, Ayvakit, had previously been approved as the first treatment for a small subset of patients with a mutation of the cancer called gastrointestinal stromal tumor. (https://reut.rs/3fTrmnN)
(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Amy Caren Daniel)
